Santoro, FrancescoNuñez-Gil, Ivan JavierVitale, EnricaViana-Llamas, Maria CReche-Martinez, BegoñaRomero-Pareja, RodolfoFeltez Guzman, GiselaFernandez Rozas, InmaculadaUribarri, AitorBecerra-Muñoz, Víctor ManuelAlfonso-Rodriguez, EmilioGarcia-Aguado, MarcosHuang, JiaOrtega-Armas, María ElizabethGarcia Prieto, Juan FCorral Rubio, Eva MariaUgo, FabrizioBianco, MatteoMulet, AlbaRaposeiras-Roubin, SergioJativa Mendez, Jorge LuisEspejo Paeres, CarolinaAlbarrán, Adrián RodríguezMarín, FranciscoGuerra, FedericoAkin, IbrahimCortese, BernardoRamakrishna, HarishMacaya, CarlosFernandez-Ortiz, AntonioBrunetti, Natale Daniele2023-05-032023-05-032021-10-05http://hdl.handle.net/10668/20155Standard therapy for COVID-19 is continuously evolving. Autopsy studies showed high prevalence of platelet-fibrin-rich microthrombi in several organs. The aim of the study was therefore to evaluate the safety and efficacy of antiplatelet therapy (APT) in hospitalised patients with COVID-19 and its impact on survival. 7824 consecutive patients with COVID-19 were enrolled in a multicentre international prospective registry (Health Outcome Predictive Evaluation-COVID-19 Registry). Clinical data and in-hospital complications were recorded. Data on APT, including aspirin and other antiplatelet drugs, were obtained for each patient. During hospitalisation, 730 (9%) patients received single APT (93%, n=680) or dual APT (7%, n=50). Patients treated with APT were older (74±12 years vs 63±17 years, p APT during hospitalisation for COVID-19 could be associated with lower mortality risk and shorter duration of mechanical ventilation, without increased risk of bleeding. NCT04334291.enCOVID-19clinicalpharmacologyAgedCOVID-19FemaleHospital MortalityHospitalizationHumansMaleMiddle AgedPlatelet Aggregation InhibitorsRegistriesRespiration, ArtificialCOVID-19 Drug Treatmentresearch article34611045open access10.1136/heartjnl-2021-3195521468-201XPMC8494537https://europepmc.org/articles/pmc8494537?pdf=renderhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494537/pdf